Sign in
SuspendedEarly phase 1

Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer

Key facts

Who runs it
Wondercel Biotech (ShenZhen)
Where
China2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
Phase
Early phase 1
People taking part
30 people, planned
Started
23 Oct 2024
Expected to end
30 Dec 2027
Type of study
Interventional
Treatments tested
  • Universal CAR-T cells injection for treating mCRC
Record updated
7 May 2026
Why it stopped
Because the implementation of the new regulation policy by the Chinese authority

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 48 criteriaShow less

Who can take part

  • Age: ≥18 years and ≤75 years old
  • Pathological Diagnosis: Pathologically confirmed metastatic colorectal cancer with radiographically confirmed metastatic lesions (e.g., CT or MRI)
  • GCC Expression: Tumor lesions assessed by immunohistochemistry (IHC) showing GCC expression ≥1+ in ≥50% of the area (randomly select at least 5 fields from tumor regions for evaluation; at least 5 unstained slides must be provided for assessment)
  • Measurable Lesions: At least one measurable lesion per RECIST 1.1 criteria; measurable lesions should not have received prior radiotherapy or interventional local therapy (lesions in previously irradiated or locally treated fields may be selected as target lesions if confirmed to have progressed)
  • Prior Treatment: Participants with advanced colorectal cancer who have progressed or are intolerant after ≥2 lines of standard therapy (with clear documentation)
  • ECOG Performance Status: 0 or 1
  • Expected Survival: ≥90 days (as assessed by the investigator based on the participant's clinical condition)
  • Organ Function:
  • Absolute neutrophil count ≥1.5 × 10⁹/L
  • Platelet count ≥80 × 10⁹/L
  • Hemoglobin ≥9 g/dL
  • Liver function:; Total bilirubin ≤1.5 × ULN (≤2.0 × ULN for Gilbert's syndrome); AST and ALT ≤5 × ULN
  • INR <1.3 (INR <3 for participants on anticoagulant therapy)
  • Serum creatinine ≤1.5 mg/dL (132.6 μmol/L) or eGFR ≥50 mL/min/1.73 m²
  • Cardiac ejection fraction >50%
  • Bleeding Risk: No active bleeding or bleeding tendency
  • Fertility Requirements:
  • Women of childbearing potential must have a negative pregnancy test (serum or urine) within 7 days prior to enrollment and agree to use effective contraception during treatment and for 8 weeks after the last dose
  • Male participants must also use effective contraception during treatment and for 8 weeks after the last dose
  • Informed Consent: Participants voluntarily enroll in the study, provide signed informed consent, demonstrate good compliance, and cooperate with follow-up

Who cannot take part

  • • Received chemotherapy, targeted therapy, monoclonal antibody therapy, or traditional Chinese medicine anti-tumor therapy within 14 days prior to cell collection
  • • Participated in another drug clinical trial within 4 weeks prior to study initiation
  • History of myocarditis, cardiomyopathy, or myocardial infarction within 6 months prior to enrollment (unless cardiac function has recovered as confirmed by the investigator)
  • • Prior anti-tumor treatment-related toxicities not recovered to ≤Grade 1 or to levels specified in the inclusion/exclusion criteria
  • • Clinically significant pulmonary impairment due to lung comorbidities, including but not limited to underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, or severe COPD within 3 months prior to enrollment), any autoimmune, connective tissue, or inflammatory disorders involving the lungs (e.g., rheumatoid arthritis, sarcoidosis), or prior pneumonectomy
  • • Any of the following cardiovascular or cerebrovascular diseases or risk factors:
  • NYHA Class III or IV heart failure
  • Uncontrolled arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) or requiring long-term anti-arrhythmic therapy
  • Uncontrolled hypertension (systolic BP >160 mmHg or diastolic BP >100 mmHg)
  • History of ischemic or hemorrhagic stroke (unless stable for >6 months with no sequelae)
  • History of DVT or PE (unless on stable anticoagulant therapy for ≥6 months)
  • Significantly elevated troponin or BNP/NT-proBNP levels suggestive of potential cardiac injury or dysfunction
  • • Coagulation disorders or bleeding diathesis
  • • History of substance abuse (including psychiatric drugs) that cannot be discontinued or history of psychiatric disorders
  • • Uncontrolled or active fungal, bacterial, viral, or other infections
  • • Known HIV infection; known active syphilis; or active hepatitis B (HBsAg-positive and HBV-DNA ≥500 IU/mL or above the lower limit of detection, whichever is higher) or hepatitis C (anti-HCV-positive and HCV-RNA above the lower limit of detection)
  • • Active autoimmune disease requiring systemic treatment within 2 years (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism); physiologic corticosteroid replacement therapy (e.g., thyroxine, insulin, or corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment
  • • History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment
  • • Any condition deemed by the investigator to interfere with drug evaluation, participant safety, or study outcomes, or any other condition making the participant unsuitable for the study
  • LVEF <50%
  • • Severe allergic reaction history to key study treatments (including fludarabine, cyclophosphamide, mycophenolate sodium, tocilizumab, and anti-infective agents used during preconditioning)
  • • Pregnant or breastfeeding women
  • QTcF >480 ms on screening ECG
  • Uncontrolled intracranial lesions (e.g., brain tumors, aneurysms)
  • • Non-healing wounds or fractures for a prolonged period
  • • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage despite appropriate intervention
  • • Female participants unwilling to use contraception from informed consent through 6 months after CAR-T cell infusion
  • • Participants with leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or active/symptomatic CNS metastases not treated locally

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is an investigator initiated trial to assess the efficacy and safety of a GCC-targeting CAR-T therapy (REVO-UWD-01) in the metastatic colorectal cancer. It also aims to explore the feasibility of using a novel universal CAR-T cell platform.

The group in the trial

  • Single dose injection of REVO-UWD-01Treatment being tested

    Dose escalation will be performed for the single dose injection of REVO-UWD-01 for treating mCRC

    Treatment: Universal CAR-T cells injection for treating mCRC

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Clinical Study on the Safety and Efficacy of Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer
Record updated
7 May 2026